Aaron Deykin, MD, is a GentiBio Board Director and the Chief Medical Officer and Head of Research and Development at Upstream Bio, a biotechnology company in Waltham MA. In that role, he leads the company’s development vision, providing clinical expertise, translational science direction, regulatory strategy to drive Upstream Bio’s programs to approval. Previously, Aaron held roles of increasing responsibility at Biogen including leadership positions in Clinical Development in which he led the approval of several drugs for multiple sclerosis and also served as SVP of Clinical Sciences overseeing Biostatistics, Statistical Programming, Biomarkers, Clinical Pharmacology, Epidemiology, and Clinical Operations for Biogen’s pipeline globally. Before moving to industry, Aaron was Assistant Professor of Medicine at Harvard Medical School and a member of the Pulmonary and Critical Care faculty at Brigham and Women’s Hospital. In that capacity, Aaron led the medical activities of the Lung Transplantation Program, directed the Pulmonary Function Testing Laboratory, and serving as the Associate Director of the Asthma Research Center. Aaron has been awarded board certification in Internal Medicine, Pulmonary Disease, and Critical Care Medicine, and holds an MD from Harvard Medical School and an AB from Dartmouth College.
Aaron Deykin, MD
CMO, Head of R&D, Upstream Bio, Board Director